• Identify new and promising biomarkers for diseases characterized by progressive joint destruction
• Define the knowledge gaps and research opportunities to advance the understanding and use of biomarkers as surrogate endpoints in clinical trials for diseases characterized by progressive joint destruction

Agenda

Moderator: Kenneth D. Brandt, M.D., Indiana University School of Medicine

Introductory Remarks: Suzanne Serrate-Sztein, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases

Session I. Imaging Technologies

Imaging Markers of Joint Destruction and Repair
Charles G. Peterfy, M.D., Ph.D., University of California, San Francisco, and Synarc, Inc.

Imaging Biomarkers in Back Pain
Robert D. Boutin, M.D., Veterans Affairs Medical Center, San Diego, University of California, San Diego

Imaging Biomarkers in Osteoarthritis
Harry Genant, M.D., University of California, San Francisco

Imaging Technology for Osteoarthritis
Mark E. Brezinski, M.D., Ph.D., Massachusetts General Hospital

Session II. Inflammatory and Genetic Markers

Cytokine Expression in Arthritis
Gary S. Firestein, M.D., University of California, San Diego

Genetic and Major Histocompatibility Complex Markers of Disease Severity in Rheumatoid Arthritis
Cornelia M. Weyand, M.D., Ph.D., Mayo Foundation

Discussion

Session III. Biochemical Markers of Cartilage Breakdown and Repair

Serum Markers of Joint Metabolism
Eugene J-M.A. Thonar, Ph.D., Rush Medical College

Molecular Markers in Osteoarthritis
Stefan L. Lohmander, M.D., Ph.D., University of Lund, Sweden

Collagen Type II Cross-Linked Telopeptides: A Promising Marker of Cartilage Degradation in Arthritis
David Eyre, Ph.D., University of Washington

Synovial Fluid Markers of Osteoarthritis
Kenneth D. Brandt, M.D.

Summary and Conclusions

Overview  Agenda  Registration  Conference Abstracts
  Hotel & Travel  Selected References 
Remote Video Conference Participation  Contact  NIH Home Page